Home > Journals > Minerva Endocrinology > Past Issues > Minerva Endocrinologica 2002 June;27(2) > Minerva Endocrinologica 2002 June;27(2):127-40

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS   

Minerva Endocrinologica 2002 June;27(2):127-40

Copyright © 2002 EDIZIONI MINERVA MEDICA

language: English

Tamoxifen, raloxifene and the prevention of breast cancer

Bentrem D. J., Craig Jordan V.


PDF


The recognition of a new group of drugs, now named selective estrogen receptor modulators (SERMs) has revolutionized prospects for the prevention of breast cancer. New agents will continue to be tested against tamoxifen, the first SERM and an established treatment of ER positive breast cancer. Raloxifene a related SERM is used to treat and prevent osteoporosis with the potential beneficial side effect of preventing breast cancer. The Study of Tamoxifen and Raloxifene (STAR) trial will establish whether raloxifene is an improvement over tamoxifen. Most importantly, emerging information about the molecular pharmacology of SERMs will be used to decipher the mechanism of action at specific target sites around a woman's body. This knowledge can be used to design new SERMs and advance the prospects for multifunctional medicine to prevent breast cancer, osteoporosis and coronary heart disease.

top of page